StemCell Therapy

Updated: 2016-02-29

CSC Pharmaceuticals International

Listed in Pharmaceutical Drugs

(91)-(22)-65302901

Padhya Building, 2nd Floor, 11, Bhaskar Bhau Lane, Gamdevi Mumbai - 400007, Maharashtra, India

Description: CSC Pharmaceuticals International, Mumbai, India We, CSC Pharmaceuticals are offering Indian pharmaceutical drugs, pharmaceutical health Read more...

Updated: 2015-08-12

admin

09810663976

D 2/2, Ganga Triveni Apartments, Sector 9, Rohini New Delhi - 110085 Delhi, India

Description: G V Biomedicals, New Delhi, Delhi, India Supplier of Biotechnology & Biomedical Products. With a Read more...

Updated: 2015-08-12

admin

+91-11-24636224 /11-24636225

824/3, Sukhdev Nagar, Kotla Mubarakpur, New Delhi 110003, India

Description: TechnoConcept (India) Pvt. Ltd., New Delhi, Delhi, India Supplier of Bioinformatics Software and Molecular Biology Read more...

Updated: 2015-08-11

admin

+91(22)43434545, 43434535

1st Floor, SaneGuruji Building, Veer Sawarkar Marg, Opposite Siddhivinayak Temple, Prabhadevi, Mumbai (Suburban), Maharashtra, India

Description: Indian Dental Association, Mumbai, Maharashtra, India Independent and Recognized Voice of Dental Professionals. The Indian Read more...

Updated: 2015-08-11

admin

+91-120-4292758

Description: GenPro Biotech, Noida, Uttar Pradesh, India Supplier of Chemicals. GenPro Biotech was founded about a Read more...

Updated: 2015-08-10

admin

+91 80 4262 7200

75A, 15th Cross, 1st Phase, J.P.Nagar, Bangalore - 560078

Description: Semler Research Center, Bangalore, Karnataka, India Service Provider. Semler Research Center (SRC) is part of Read more...

Updated: 2015-08-10

admin

(+91)-11-45035753, (+91)-11-28753658

Building NO: 1333, 4th Floor, Office No:412, Durga Chamber, Desh Bandhu Gupta Road, Karol Bagh, New Delhi- 110005. (India)

Description: Biolinkk, New Delhi, Delhi, India Supplier of Products & Services to Life Science Research, Industrial Read more...

Updated: 2015-08-08

admin

91-11-27677960, 27674615, 27670742, +91-11-47020100

A-2/3, IIIrd Floor, Lusa Tower, Azadpur Commercial Complex, Delhi-110033, India

Description: Titan Biotech Limited, New Delhi, Delhi, India Providing good quality of Biological Products. TITAN BIOTECH Read more...

Updated: 2015-08-08

admin

1-631-559-9269 Fax: 1-631-938-8127

45-16 Ramsey Road, Shirley, NY 11967, USA

Description: Creative Biomart, New York, USA Product Development and Distribution. Creative Biomart provides quality recombinant proteins, Read more...

Updated: 2015-08-06

admin

+91-0171-2643080 , 2601773

Guru Nanak Gurdwara, New Pratap Nagar, Ambala, Haryana 134003, India

Description: Company Manufacturer & Supplier of Scientific and Laboratory Equipment. Scientific instrumentation industry has been playing Read more...

Updated: 2016-02-09

Added by PharmaTechnologyIndex.com Pvt Ltd

Categories: Equipments, Technology

October 30, 2015, October 31, 2015, November 1, 2015

Plot No. 5, Part II, Scheme No 78, Near Life Care Hospital, Vijay Nagar, Indore, Madhya Pradesh 452010

91 987 961 6665

Description: PharmaTech Expo, Indore, India PharmaTechnologyIndex.com Pvt. Ltd, a KNS group company is delighted to invite Read more...

Updated: 2015-10-16

Added by Messe Dusseldorf GmbH

Categories: Equipments

November 16, 2015, November 17, 2015, November 18, 2015

P.O.B. 10 10 06, D-40001 Duesseldorf Stockumer Kirchstrae 61, D-40474 Duesseldorf, Germany

49 (0)211 / 4560-7618

Description: Compamed, Dusseldorf, Germany Compamed 2015 is one of the finest event for the medical fraternity. Read more...

Updated: 2015-11-13

Added by we.CONECT Global Leaders GmbH

Categories: Technology

November 16, 2015, November 17, 2015

Los-Angeles-Platz 1, 10789 Berlin, Germany

49 (0)30 52 10 70 3 0

Description: Pharma M2R Minds, Berlin, Germany Maintenance processes in the pharmaceutical industry are subject to very Read more...

Updated: 2015-11-09

Added by Imapac Media

Categories: Biotechnology

November 17, 2015, November 18, 2015

Tel Aviv, Israel

65 3109 0121

Description: Biologics World Israel, Tel Aviv, Israel The environment of innovation and entrepreneurship in Israel has Read more...

Updated: 2015-11-12

Added by BioGenesis Conferences

Categories: Technology

November 18, 2015, November 19, 2015, November 20, 2015

J.N.Tata Auditorium, Indian Institute of Sciences Bengaluru, India

Description: Global Cancer Summit, Bangalore, India The conference will cover areas like prevention, early diagnosis, economics Read more...

Updated: 2016-02-09

Added by Japan Management Association

Categories: Equipments

November 25, 2015, November 26, 2015, November 27, 2015

3-11-1 Ariake, Koto-ku, Tokyo, Japan

81-3-3434-1988

Description: Hospex Japan, Tokyo, Japan Hospex Japan 2015 is an International Healthcare Engineering Exhibition. The show Read more...

Updated: 2015-11-16

Added by Cogora Limited

Categories: Technology

November 26, 2015

24-26 Newport Rd, Cardiff, South Glamorgan CF24 0DD, United Kingdom

44 (0)207 214 0693

Description: Nursing in Practice, Cardiff, UK Nursing in Practice will be returning to Cardiff this year Read more...

Updated: 2015-11-19

Added by Worldwide Business Research

See the original post here:
Home - Biotechnology Business Directory

We are living in the midst of a biotechnology revolution.

In the not too distant future, organ transplants will be a thing of the past. Doctors will use your DNA to determine treatment options. And these treatments will be available for animals and humans alike. Fueling all of this change is biotechnology. You can be one of these innovators not only by becoming a researcher, but also by following a variety of other career paths, including becoming a doctor, veterinarian, patent lawyer, health inspector, orenvironmental biotechnologist.

We prepare students for transfer to a four-year college to major in biology, biochemistry, pharmacology, molecular genetics, immunology, and related fields. Our program is also good preparation for medical, veterinary, dental, and pharmaceutical school and it provides the robust, interdisciplinary training modern baccalaureate science programs demand.

You don't have to move hundreds of miles away to work in biotechnology. We now have many biotechnology employers right in the area. They NEED YOU to be successful.

Biotechnology students at JCC perform on-site research in multiple areas, including immunology, breast cancer, heartworm, and Lyme disease. Students can gain even more experience by taking part in the Science Undergraduate Research Initiative: Biotech(SURI). We're also involved with area high schools through the HURI SURI program, which is designed to give high school students a chance to perform actual research through an interdisciplinary, college level course called Biology: A Molecular Approach.

Several biotechnology students attended the Experimental Biology Conference in Washington, DC in April 2011 and the American Association of Immunologists meeting in Boston in May 2012.

See the article here:
Biotechnology | Jamestown Community College

Background Information

SOS Children offer a complete download of this selection for schools for use on schools intranets. SOS Children is the world's largest charity giving orphaned and abandoned children the chance of family life.

Biotechnology is technology based on biology, especially when used in agriculture, food science, and medicine. The United Nations Convention on Biological Diversity defines biotechnology as:

Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use.

Biotechnology is often used to refer to genetic engineering technology of the 21st century, however the term encompasses a wider range and history of procedures for modifying biological organisms according to the needs of humanity, going back to the initial modifications of native plants into improved food crops through artificial selection and hybridization. Bioengineering is the science upon which all biotechnological applications are based. With the development of new approaches and modern techniques, traditional biotechnology industries are also acquiring new horizons enabling them to improve the quality of their products and increase the productivity of their systems.

Before 1971, the term, biotechnology, was primarily used in the food processing and agriculture industries. Since the 1970s, it began to be used by the Western scientific establishment to refer to laboratory-based techniques being developed in biological research, such as recombinant DNA or tissue culture-based processes, or horizontal gene transfer in living plants, using vectors such as the Agrobacterium bacteria to transfer DNA into a host organism. In fact, the term should be used in a much broader sense to describe the whole range of methods, both ancient and modern, used to manipulate organic materials to reach the demands of food production. So the term could be defined as, "The application of indigenous and/or scientific knowledge to the management of (parts of) microorganisms, or of cells and tissues of higher organisms, so that these supply goods and services of use to the food industry and its consumers.

Biotechnology combines disciplines like genetics, molecular biology, biochemistry, embryology and cell biology, which are in turn linked to practical disciplines like chemical engineering, information technology, and robotics. Patho-biotechnology describes the exploitation of pathogens or pathogen derived compounds for beneficial effect.

The most practical use of biotechnology, which is still present today, is the cultivation of plants to produce food suitable to humans. Agriculture has been theorized to have become the dominant way of producing food since the Neolithic Revolution. The processes and methods of agriculture have been refined by other mechanical and biological sciences since its inception. Through early biotechnology, farmers were able to select the best suited and highest-yield crops to produce enough food to support a growing population. Other uses of biotechnology were required as crops and fields became increasingly large and difficult to maintain. Specific organisms and organism by-products were used to fertilize, restore nitrogen, and control pests. Throughout the use of agriculture farmers have inadvertently altered the genetics of their crops through introducing them to new environments and breeding them with other plants--one of the first forms of biotechnology. Cultures such as those in Mesopotamia, Egypt, and Pakistan developed the process of brewing beer. It is still done by the same basic method of using malted grains (containing enzymes) to convert starch from grains into sugar and then adding specific yeasts to produce beer. In this process the carbohydrates in the grains were broken down into alcohols such as ethanol. Ancient Indians also used the juices of the plant Ephedra Vulgaris and used to call it Soma. Later other cultures produced the process of Lactic acid fermentation which allowed the fermentation and preservation of other forms of food. Fermentation was also used in this time period to produce leavened bread. Although the process of fermentation was not fully understood until Louis Pasteurs work in 1857, it is still the first use of biotechnology to convert a food source into another form.

Combinations of plants and other organisms were used as medications in many early civilizations. Since as early as 200 BC, people began to use disabled or minute amounts of infectious agents to immunize themselves against infections. These and similar processes have been refined in modern medicine and have led to many developments such as antibiotics, vaccines, and other methods of fighting sickness.

In the early twentieth century scientists gained a greater understanding of microbiology and explored ways of manufacturing specific products. In 1917, Chaim Weizmann first used a pure microbiological culture in an industrial process, that of manufacturing corn starch using Clostridium acetobutylicum to produce acetone, which the United Kingdom desperately needed to manufacture explosives during World War I.

The field of modern biotechnology is thought to have largely begun on June 16, 1980, when the United States Supreme Court ruled that a genetically-modified microorganism could be patented in the case of Diamond v. Chakrabarty. Indian-born Ananda Chakrabarty, working for General Electric, had developed a bacterium (derived from the Pseudomonas genus) capable of breaking down crude oil, which he proposed to use in treating oil spills.

Revenue in the industry is expected to grow by 12.9% in 2008. Another factor influencing the biotechnology sector's success is improved intellectual property rights legislation -- and enforcement -- worldwide, as well as strengthened demand for medical and pharmaceutical products to cope with an ageing, and ailing, U.S. population .

Rising demand for biofuels is expected to be good news for the biotechnology sector, with the Department of Energy estimating ethanol usage could reduce U.S. petroleum-derived fuel consumption by up to 30% by 2030. The biotechnology sector has allowed the U.S. farming industry to rapidly increase its supply of corn and soybeans -- the main inputs into biofuels -- by developing genetically-modified seeds which are resistant to pests and drought. By boosting farm productivity, biotechnology plays a crucial role in ensuring that biofuel production targets are met.

Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non food (industrial) uses of crops and other products (e.g. biodegradable plastics, vegetable oil, biofuels), and environmental uses.

For example, one application of biotechnology is the directed use of organisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, clean up sites contaminated by industrial activities ( bioremediation), and also to produce biological weapons.

A series of derived terms have been coined to identify several branches of biotechnology, for example:

In medicine, modern biotechnology finds promising applications in such areas as

Pharmacogenomics is the study of how the genetic inheritance of an individual affects his/her bodys response to drugs. It is a coined word derived from the words pharmacology and genomics. It is hence the study of the relationship between pharmaceuticals and genetics. The vision of pharmacogenomics is to be able to design and produce drugs that are adapted to each persons genetic makeup.

Pharmacogenomics results in the following benefits:

1. Development of tailor-made medicines. Using pharmacogenomics, pharmaceutical companies can create drugs based on the proteins, enzymes and RNA molecules that are associated with specific genes and diseases. These tailor-made drugs promise not only to maximize therapeutic effects but also to decrease damage to nearby healthy cells.

2. More accurate methods of determining appropriate drug dosages. Knowing a patients genetics will enable doctors to determine how well his/ her body can process and metabolize a medicine. This will maximize the value of the medicine and decrease the likelihood of overdose.

3. Improvements in the drug discovery and approval process. The discovery of potential therapies will be made easier using genome targets. Genes have been associated with numerous diseases and disorders. With modern biotechnology, these genes can be used as targets for the development of effective new therapies, which could significantly shorten the drug discovery process.

4. Better vaccines. Safer vaccines can be designed and produced by organisms transformed by means of genetic engineering. These vaccines will elicit the immune response without the attendant risks of infection. They will be inexpensive, stable, easy to store, and capable of being engineered to carry several strains of pathogen at once.

Most traditional pharmaceutical drugs are relatively simple molecules that have been found primarily through trial and error to treat the symptoms of a disease or illness. Biopharmaceuticals are large biological molecules known as proteins and these usually target the underlying mechanisms and pathways of a malady (but not always, as is the case with using insulin to treat type 1 diabetes mellitus, as that treatment merely addresses the symptoms of the disease, not the underlying cause which is autoimmunity); it is a relatively young industry. They can deal with targets in humans that may not be accessible with traditional medicines. A patient typically is dosed with a small molecule via a tablet while a large molecule is typically injected.

Small molecules are manufactured by chemistry but larger molecules are created by living cells such as those found in the human body: for example, bacteria cells, yeast cells, animal or plant cells.

Modern biotechnology is often associated with the use of genetically altered microorganisms such as E. coli or yeast for the production of substances like synthetic insulin or antibiotics. It can also refer to transgenic animals or transgenic plants, such as Bt corn. Genetically altered mammalian cells, such as Chinese Hamster Ovary (CHO) cells, are also used to manufacture certain pharmaceuticals. Another promising new biotechnology application is the development of plant-made pharmaceuticals.

Biotechnology is also commonly associated with landmark breakthroughs in new medical therapies to treat hepatitis B, hepatitis C, cancers, arthritis, haemophilia, bone fractures, multiple sclerosis, and cardiovascular disorders. The biotechnology industry has also been instrumental in developing molecular diagnostic devices than can be used to define the target patient population for a given biopharmaceutical. Herceptin, for example, was the first drug approved for use with a matching diagnostic test and is used to treat breast cancer in women whose cancer cells express the protein HER2.

Modern biotechnology can be used to manufacture existing medicines relatively easily and cheaply. The first genetically engineered products were medicines designed to treat human diseases. To cite one example, in 1978 Genentech developed synthetic humanized insulin by joining its gene with a plasmid vector inserted into the bacterium Escherichia coli. Insulin, widely used for the treatment of diabetes, was previously extracted from the pancreas of abattoir animals (cattle and/or pigs). The resulting genetically engineered bacterium enabled the production of vast quantities of synthetic human insulin at relatively low cost, although the cost savings was used to increase profits for manufacturers, not passed on to consumers or their healthcare providers. According to a 2003 study undertaken by the International Diabetes Federation (IDF) on the access to and availability of insulin in its member countries, synthetic 'human' insulin is considerably more expensive in most countries where both synthetic 'human' and animal insulin are commercially available: e.g. within European countries the average price of synthetic 'human' insulin was twice as high as the price of pork insulin. Yet in its position statement, the IDF writes that "there is no overwhelming evidence to prefer one species of insulin over another" and "[modern, highly-purified] animal insulins remain a perfectly acceptable alternative.

Modern biotechnology has evolved, making it possible to produce more easily and relatively cheaply human growth hormone, clotting factors for hemophiliacs, fertility drugs, erythropoietin and other drugs. Most drugs today are based on about 500 molecular targets. Genomic knowledge of the genes involved in diseases, disease pathways, and drug-response sites are expected to lead to the discovery of thousands more new targets.

Genetic testing involves the direct examination of the DNA molecule itself. A scientist scans a patients DNA sample for mutated sequences.

There are two major types of gene tests. In the first type, a researcher may design short pieces of DNA (probes) whose sequences are complementary to the mutated sequences. These probes will seek their complement among the base pairs of an individuals genome. If the mutated sequence is present in the patients genome, the probe will bind to it and flag the mutation. In the second type, a researcher may conduct the gene test by comparing the sequence of DNA bases in a patients gene to disease in healthy individuals or their progeny.

Genetic testing is now used for:

Some genetic tests are already available, although most of them are used in developed countries. The tests currently available can detect mutations associated with rare genetic disorders like cystic fibrosis, sickle cell anaemia, and Huntingtons disease. Recently, tests have been developed to detect mutation for a handful of more complex conditions such as breast, ovarian, and colon cancers. However, gene tests may not detect every mutation associated with a particular condition because many are as yet undiscovered, and the ones they do detect may present different risks to different people and populations.

Several issues have been raised regarding the use of genetic testing:

1. Absence of cure. There is still a lack of effective treatment or preventive measures for many diseases and conditions now being diagnosed or predicted using gene tests. Thus, revealing information about risk of a future disease that has no existing cure presents an ethical dilemma for medical practitioners.

2. Ownership and control of genetic information. Who will own and control genetic information, or information about genes, gene products, or inherited characteristics derived from an individual or a group of people like indigenous communities? At the macro level, there is a possibility of a genetic divide, with developing countries that do not have access to medical applications of biotechnology being deprived of benefits accruing from products derived from genes obtained from their own people. Moreover, genetic information can pose a risk for minority population groups as it can lead to group stigmatization.

At the individual level, the absence of privacy and anti-discrimination legal protections in most countries can lead to discrimination in employment or insurance or other misuse of personal genetic information. This raises questions such as whether genetic privacy is different from medical privacy.

3. Reproductive issues. These include the use of genetic information in reproductive decision-making and the possibility of genetically altering reproductive cells that may be passed on to future generations. For example, germline therapy forever changes the genetic make-up of an individuals descendants. Thus, any error in technology or judgment may have far-reaching consequences. Ethical issues like designer babies and human cloning have also given rise to controversies between and among scientists and bioethicists, especially in the light of past abuses with eugenics.

4. Clinical issues. These centre on the capabilities and limitations of doctors and other health-service providers, people identified with genetic conditions, and the general public in dealing with genetic information.

5. Effects on social institutions. Genetic tests reveal information about individuals and their families. Thus, test results can affect the dynamics within social institutions, particularly the family.

6. Conceptual and philosophical implications regarding human responsibility, free will vis--vis genetic determinism, and the concepts of health and disease.

Gene therapy may be used for treating, or even curing, genetic and acquired diseases like cancer and AIDS by using normal genes to supplement or replace defective genes or to bolster a normal function such as immunity. It can be used to target somatic (i.e., body) or germ (i.e., egg and sperm) cells. In somatic gene therapy, the genome of the recipient is changed, but this change is not passed along to the next generation. In contrast, in germline gene therapy, the egg and sperm cells of the parents are changed for the purpose of passing on the changes to their offspring.

There are basically two ways of implementing a gene therapy treatment:

1. Ex vivo, which means outside the body Cells from the patients blood or bone marrow are removed and grown in the laboratory. They are then exposed to a virus carrying the desired gene. The virus enters the cells, and the desired gene becomes part of the DNA of the cells. The cells are allowed to grow in the laboratory before being returned to the patient by injection into a vein.

2. In vivo, which means inside the body No cells are removed from the patients body. Instead, vectors are used to deliver the desired gene to cells in the patients body.

Currently, the use of gene therapy is limited. Somatic gene therapy is primarily at the experimental stage. Germline therapy is the subject of much discussion but it is not being actively investigated in larger animals and human beings.

As of June 2001, more than 500 clinical gene-therapy trials involving about 3,500 patients have been identified worldwide. Around 78% of these are in the United States, with Europe having 18%. These trials focus on various types of cancer, although other multigenic diseases are being studied as well. Recently, two children born with severe combined immunodeficiency disorder (SCID) were reported to have been cured after being given genetically engineered cells.

Gene therapy faces many obstacles before it can become a practical approach for treating disease. At least four of these obstacles are as follows:

1. Gene delivery tools. Genes are inserted into the body using gene carriers called vectors. The most common vectors now are viruses, which have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Scientists manipulate the genome of the virus by removing the disease-causing genes and inserting the therapeutic genes. However, while viruses are effective, they can introduce problems like toxicity, immune and inflammatory responses, and gene control and targeting issues.

2. Limited knowledge of the functions of genes. Scientists currently know the functions of only a few genes. Hence, gene therapy can address only some genes that cause a particular disease. Worse, it is not known exactly whether genes have more than one function, which creates uncertainty as to whether replacing such genes is indeed desirable.

3. Multigene disorders and effect of environment. Most genetic disorders involve more than one gene. Moreover, most diseases involve the interaction of several genes and the environment. For example, many people with cancer not only inherit the disease gene for the disorder, but may have also failed to inherit specific tumor suppressor genes. Diet, exercise, smoking and other environmental factors may have also contributed to their disease.

4. High costs. Since gene therapy is relatively new and at an experimental stage, it is an expensive treatment to undertake. This explains why current studies are focused on illnesses commonly found in developed countries, where more people can afford to pay for treatment. It may take decades before developing countries can take advantage of this technology.

The Human Genome Project is an initiative of the U.S. Department of Energy (DOE) that aims to generate a high-quality reference sequence for the entire human genome and identify all the human genes.

The DOE and its predecessor agencies were assigned by the U.S. Congress to develop new energy resources and technologies and to pursue a deeper understanding of potential health and environmental risks posed by their production and use. In 1986, the DOE announced its Human Genome Initiative. Shortly thereafter, the DOE and National Institutes of Health developed a plan for a joint Human Genome Project (HGP), which officially began in 1990.

The HGP was originally planned to last 15 years. However, rapid technological advances and worldwide participation accelerated the completion date to 2003 (making it a 13 year project). Already it has enabled gene hunters to pinpoint genes associated with more than 30 disorders.

Cloning involves the removal of the nucleus from one cell and its placement in an unfertilized egg cell whose nucleus has either been deactivated or removed.

There are two types of cloning:

1. Reproductive cloning. After a few divisions, the egg cell is placed into a uterus where it is allowed to develop into a fetus that is genetically identical to the donor of the original nucleus.

2. Therapeutic cloning. The egg is placed into a Petri dish where it develops into embryonic stem cells, which have shown potentials for treating several ailments.

In February 1997, cloning became the focus of media attention when Ian Wilmut and his colleagues at the Roslin Institute announced the successful cloning of a sheep, named Dolly, from the mammary glands of an adult female. The cloning of Dolly made it apparent to many that the techniques used to produce her could someday be used to clone human beings. This stirred a lot of controversy because of its ethical implications.

Using the techniques of modern biotechnology, one or two genes may be transferred to a highly developed crop variety to impart a new character that would increase its yield (30). However, while increases in crop yield are the most obvious applications of modern biotechnology in agriculture, it is also the most difficult one. Current genetic engineering techniques work best for effects that are controlled by a single gene. Many of the genetic characteristics associated with yield (e.g., enhanced growth) are controlled by a large number of genes, each of which has a minimal effect on the overall yield (31). There is, therefore, much scientific work to be done in this area.

Crops containing genes that will enable them to withstand biotic and abiotic stresses may be developed. For example, drought and excessively salty soil are two important limiting factors in crop productivity. Biotechnologists are studying plants that can cope with these extreme conditions in the hope of finding the genes that enable them to do so and eventually transferring these genes to the more desirable crops. One of the latest developments is the identification of a plant gene, At-DBF2, from thale cress, a tiny weed that is often used for plant research because it is very easy to grow and its genetic code is well mapped out. When this gene was inserted into tomato and tobacco cells (see RNA interference), the cells were able to withstand environmental stresses like salt, drought, cold and heat, far more than ordinary cells. If these preliminary results prove successful in larger trials, then At-DBF2 genes can help in engineering crops that can better withstand harsh environments (32). Researchers have also created transgenic rice plants that are resistant to rice yellow mottle virus (RYMV). In Africa, this virus destroys majority of the rice crops and makes the surviving plants more susceptible to fungal infections (33).

Proteins in foods may be modified to increase their nutritional qualities. Proteins in legumes and cereals may be transformed to provide the amino acids needed by human beings for a balanced diet (34). A good example is the work of Professors Ingo Potrykus and Peter Beyer on the so-called Goldenrice(discussed below).

Modern biotechnology can be used to slow down the process of spoilage so that fruit can ripen longer on the plant and then be transported to the consumer with a still reasonable shelf life. This improves the taste, texture and appearance of the fruit. More importantly, it could expand the market for farmers in developing countries due to the reduction in spoilage.

The first genetically modified food product was a tomato which was transformed to delay its ripening (35). Researchers in Indonesia, Malaysia, Thailand, Philippines and Vietnam are currently working on delayed-ripening papaya in collaboration with the University of Nottingham and Zeneca (36).

Biotechnology in cheese production: enzymes produced by micro-organisms provide an alternative to animal rennet a cheese coagulant - and an alternative supply for cheese makers. This also eliminates possible public concerns with animal-derived material, although there is currently no plans to develop synthetic milk, thus making this argument less compelling. Enzymes offer an animal-friendly alternative to animal rennet. While providing comparable quality, they are theoretically also less expensive.

About 85 million tons of wheat flour is used every year to bake bread. By adding an enzyme called maltogenic amylase to the flour, bread stays fresher longer. Assuming that 10-15% of bread is thrown away, if it could just stay fresh another 57 days then 2 million tons of flour per year would be saved. That corresponds to 40% of the bread consumed in a country such as the USA. This means more bread becomes available with no increase in input. In combination with other enzymes, bread can also be made bigger, more appetizing and better in a range of ways.

Most of the current commercial applications of modern biotechnology in agriculture are on reducing the dependence of farmers on agrochemicals. For example, Bacillus thuringiensis (Bt) is a soil bacterium that produces a protein with insecticidal qualities. Traditionally, a fermentation process has been used to produce an insecticidal spray from these bacteria. In this form, the Bt toxin occurs as an inactive protoxin, which requires digestion by an insect to be effective. There are several Bt toxins and each one is specific to certain target insects. Crop plants have now been engineered to contain and express the genes for Bt toxin, which they produce in its active form. When a susceptible insect ingests the transgenic crop cultivar expressing the Bt protein, it stops feeding and soon thereafter dies as a result of the Bt toxin binding to its gut wall. Bt corn is now commercially available in a number of countries to control corn borer (a lepidopteran insect), which is otherwise controlled by spraying (a more difficult process).

Crops have also been genetically engineered to acquire tolerance to broad-spectrum herbicide. The lack of cost-effective herbicides with broad-spectrum activity and no crop injury was a consistent limitation in crop weed management. Multiple applications of numerous herbicides were routinely used to control a wide range of weed species detrimental to agronomic crops. Weed management tended to rely on preemergence that is, herbicide applications were sprayed in response to expected weed infestations rather than in response to actual weeds present. Mechanical cultivation and hand weeding were often necessary to control weeds not controlled by herbicide applications. The introduction of herbicide tolerant crops has the potential of reducing the number of herbicide active ingredients used for weed management, reducing the number of herbicide applications made during a season, and increasing yield due to improved weed management and less crop injury. Transgenic crops that express tolerance to glyphosate, glufosinate and bromoxynil have been developed. These herbicides can now be sprayed on transgenic crops without inflicting damage on the crops while killing nearby weeds (37).

From 1996 to 2001, herbicide tolerance was the most dominant trait introduced to commercially available transgenic crops, followed by insect resistance. In 2001, herbicide tolerance deployed in soybean, corn and cotton accounted for 77% of the 626,000 square kilometres planted to transgenic crops; Bt crops accounted for 15%; and "stacked genes" for herbicide tolerance and insect resistance used in both cotton and corn accounted for 8% (38).

Biotechnology is being applied for novel uses other than food. For example, oilseed can be modified to produce fatty acids for detergents, substitute fuels and petrochemicals. Potatos, tomatos, rice, tobacco, lettuce, safflowers, and other plants have been genetically-engineered to produce insulin and certain vaccines. If future clinical trials prove successful, the advantages of edible vaccines would be enormous, especially for developing countries. The transgenic plants may be grown locally and cheaply. Homegrown vaccines would also avoid logistical and economic problems posed by having to transport traditional preparations over long distances and keeping them cold while in transit. And since they are edible, they will not need syringes, which are not only an additional expense in the traditional vaccine preparations but also a source of infections if contaminated. In the case of insulin grown in transgenic plants, it is well-established that the gastrointestinal system breaks the protein down therefore this could not currently be administered as an edible protein. However, it might be produced at significantly lower cost than insulin produced in costly, bioreactors. For example, Calgary, Canada-based SemBioSys Genetics, Inc. reports that its safflower-produced insulin will reduce unit costs by over 25% or more and reduce the capital costs associated with building a commercial-scale insulin manufacturing facility by approximately over $100 million compared to traditional biomanufacturing facilities.

There is another side to the agricultural biotechnology issue however. It includes increased herbicide usage and resultant herbicide resistance, "super weeds," residues on and in food crops, genetic contamination of non-GM crops which hurt organic and conventional farmers, damage to wildlife from glyphosate, etc.

Biotechnological engineering or biological engineering is a branch of engineering that focuses on biotechnologies and biological science. It includes different disciplines such as biochemical engineering, biomedical engineering, bio-process engineering, biosystem engineering and so on. Because of the novelty of the field, the definition of a bioengineer is still undefined. However, in general it is an integrated approach of fundamental biological sciences and traditional engineering principles.

Bioengineers are often employed to scale up bio processes from the laboratory scale to the manufacturing scale. Moreover, as with most engineers, they often deal with management, economic and legal issues. Since patents and regulation (e.g. FDA regulation in the U.S.) are very important issues for biotech enterprises, bioengineers are often required to have knowledge related to these issues.

The increasing number of biotech enterprises is likely to create a need for bioengineers in the years to come. Many universities throughout the world are now providing programs in bioengineering and biotechnology (as independent programs or specialty programs within more established engineering fields)..

More here:
Biotechnology - Wikipedia for Schools

Job Title: Bench Scientist (Job ID# 2436-1) Location: 700 Chesterfield Parkway West MO 63017 Duration: 15 months contract Anticipated Schedule: 40hours/week (M-F) Job Description: Proficient with wet chemistry and analytical instrumentation (emphasis on proteins desired). Primary roles include SDS-PAGE analysis, buffer preparation and routine testing (appearance, pH, moisture, concentration ...

Sunrise System Inc. is currently seeking for Research Associate in Spring House, PA for one of our top clients. Title: Research Associate Location: Spring House, PA 19477 Duration: 12+ months Contract Type: Contract W2 only ID: 16-03278 Job Description: The candidate should have a BS/MS in biological sciences with research experience in cellular immunology and/or cell biology including si...

Skills required: Elisa/TCell, luminex assays, BS/MS degree in Biology Please note that this is a 1+ year contract: The candidate should have a BS/MS in biological sciences with research experience in cellular immunology and/or cell biology including significant hands-on experience performing cell culture and following proper aseptic technique. The successful candidate will be able to apply diff...

Large Pharmaceutical Company in the Philadelphia, PA area is seeking a Research Scientist I to join their team for a one year contract. This is an excellent opportunity for a recent college graduate who is looking to start their career in the Pharmaceutical industry. Requirements and Qualifications: The successful candidate will be able to apply different research techniques in the work includin...

We have an immediate position for a Drug Safety Coordinator with our top pharmaceutical client , if you are interested please send your updated resume to greg @ collabinfo.com or call me at 732-788-3483 Title: Drug Safety Coordinator Duration: 6+ Months Location: Horsham, PA Global Medical Organization Case Receipt, Global Case Management, GMS Operations Description: Responsible for the r...

Job Title: Bench Scientist (Job ID# 2422-1) Location: 700 Chesterfield Pkwy W MO 63198 Duration: 15 months contract Anticipated Schedule: 40hours/week (M-F) Job Description: High throughput protein analytics laboratory needs a competent, motivated entry-level analyst. Proficient with wet chemistry and analytical instrumentation. Emphasis on proteins desired. Primary roles include SDS-PAGE ...

Job Background A Large Industry Leader based out of the North St. Paul Metro is actively seeking a new Lab Technician II for a 6-Month Contract to Permanent. This position will support research and development activities focused on strategic business markets. Job Responsibilities Synthesis and characterization of various reactive adhesives for both long-term development and short-term internal ...

Seeking an Experienced Sr. Process Chemist. Apply today! Ricerca Biosciences, LLC is a contract research organization supporting the pharmaceutical, agricultural, chemical, animal nutrition and consumer industries. Our comprehensive, integrated suite of services helps our clients meet their regulatory requirements and internal development goals. Located on a 43-acre campus in Concord, Ohio, our e...

LABORATORY TECHNICIAN REQUIREMENT #16-00368 RECRUITER: MEGAN STRAWN JOB LOCATION: LAWRENCEVILLE, NJ FEBRUARY 29, 2016 *** CANDIDATES MUST BE ABLE TO WORK ON OUR PAYROLL AS A W-2 *** Project Description: The successful candidate will provide basic laboratory support to Immunohistochemistry/Histology group within the Discovery Translational Sciences Group. The position will involve cell cult...

Are you an experienced manager who thrives in a fast-paced and engaging culture? Do you have significant experience identifying and managing CMOs, CROs and vendors? Do you envision yourself working for a financially-stable and expanding Biosimilars business? Do you have a minimum of 7+ years of relevant, progressive and hands-on experience in a similar role? Do you have a proven tr...

Research Fellow, Crystallization Technology Summary PharmaCore is seeking to hire a candidate with broad expertise in crystallization technology to assume a scientific leadership role in our dynamic R&D process chemistry group. Desired candidates will have worked extensively at the interface between process chemistry and crystallization sciences. The candidate will be primarily responsible for s...

The Director of GxP Compliance will oversee the entire function, spanning all audit disciplines included within the remit of United Therapeutics Quality Management, including all GxP audit programs and vendor/supplier audit activities. This role will also define Health Authority Inspection Management best practices for United Therapeutics as well as participate in and support associated inspection...

Our client, a not-for-profit research organization is looking to add a Clinical Program Assistant to their team. The Clinical Program Assistant will be aiding the organization in their mission to slow the progression of Huntington's Disease and provide much needed clinical benefit to patients. If you are a looking for an entry level position into clinical trials, please apply today. Qualification...

Reports To Facility Manager Initial Skills Must be able to work flexible hours Degree preferred or other related disciplines or equivalent experience. City Food Sanitation Certification PKRC will provide instruction for otherwise qualified candidates. Requires direct work related experience in food preparation and sanitation. Work Skills Must have excellent qualitative and quantitative s...

Assist in the detection of fermentation and/or manufacturing capabilities of Contract Manufacturing Organizations (CMO) for the Human Oligosaccharide Project. Assist and advice in matters regarding technology transfer of established synthesis process to CMO. Provide advice to determine cost saving measures for the production of oligosaccharides through fermentation techniques. Intervene in Technol...

Manpower is hiring Manufacturing Laboratory Technician in Winchester, KY. Candidates will be running pilot product experiments following work orders and Standard Operating Procedure (SOP). Skills: - Technical and mechanical aptitude - Forklift experience - Troubleshooting capabilities - Research laboratory experience - Data Entry - Quick learner Preferred Work Experience: (2-5 years) - P...

Description A part time clinical laboratory director is needed for a Physicians Office Laboratory. The laboratory director must be qualified by CLIA/CLIS to direct high complexity testing in the general immunology and routine chemistry specialties. Duties The laboratory director is responsible for the overall compliance of the laboratory with federal and state guidelines. This includes: Revie...

Department: National Corn to Ethanol Research Center Job Posting Description: The Ethanol Plant Operating Coordinator is responsible for the operation, maintenance, and monitoring of equipment and associated control mechanisms of an ethanol plant. They will assist in operating and troubleshooting mechanical control systems, utility equipment, and other laboratory research mechanical components ...

Job Description: The Marketing Labeling Liaison manages the planning coordination and execution of the marketing inputs to the Labeling process for client Consumer Healthcare. This role is the first point of contact for individuals authorized by MCH to request the information on new or existing packaging graphics projects based on business needs. This role manages is responsible for marketing a...

One of our top clients, a rapidly growing biotech company near the nations capital, is actively seeking their next MANAGER OF CLINICAL QA to help them audit investigator and vendor sites and systems to ensure GCP compliance. ADVANTAGES OF THIS OPPORTUNITY: CHANCE TO MAKE A DIFFERENCE Being part of a small department, this opportunity gives you a chance to play an integral role in the advancem...

View post:
Biotech Jobs - Search Biotech Job Listings | Monster.com

British Dictionary definitions for biotechnology Expand

/batknld/

(in industry) the technique of using microorganisms, such as bacteria, to perform chemical processing, such as waste recycling, or to produce other materials, such as beer and wine, cheese, antibiotics, and (using genetic engineering) hormones, vaccines, etc

Derived Forms

biotechnological (batknldkl) adjectivebiotechnologically, adverbbiotechnologist, noun

Word Origin and History for biotechnology Expand

also bio-technology, 1947, "use of machinery in relation to human needs;" 1972 in sense of "use of biological processes in industrial production," from bio- + technology.

biotechnology in Medicine Expand

biotechnology biotechnology (b'-tk-nl'-j) n.

The use of microorganisms, such as bacteria or yeasts, or biological substances, such as enzymes, to perform specific industrial or manufacturing processes. Applications include production of certain drugs, synthetic hormones, and bulk foodstuffs.

The application of the principles of engineering and technology to the life sciences.

biotechnology in Science Expand

The use of a living organism to solve an engineering problem or perform an industrial task. Using bacteria that feed on hydrocarbons to clean up an oil spill is one example of biotechnology.

The use of biological substances or techniques to engineer or manufacture a product or substance, as when cells that produce antibodies are cloned in order to study their effects on cancer cells. See more at genetic engineering.

Read more:
Biotechnology | Define Biotechnology at Dictionary.com

Various biotechnology careers include forensic DNA analyst, scientist, clinical research associate job, laboratory assistant, microbiologist, greenhouse and field technician, bioinformatics specialist, animal caretaker and many more.

Biotechnology is combining knowledge about life and living organisms with modern technology to create new systems, devices, materials, foodthat could improve human life and help preserve environment. Most biotechnology products are associated with agriculture, food industry and medicine, and logically - careers in those fields are most popular.

Average Salary (per month) for a Green House and Field Technician may range from: US $2500-3000 In India, salaries may range between: INR 15,000-30,000 (or more, depending upon the experience)

This position is usually associated with crime laboratories where DNA analysis is performed to solve legal issues. Urine, saliva, blood, semen, hairthose are the samples that could be used for DNA analysis. After sample collection, DNA is extracted and analyzed using couple methods (PCR, electrophoresis). Final results are further compared with the already known DNA profiles. Methodology is strict: properly collected and stored evidence, documentation on technical laboratory details and well written final reports are essential for successful prosecution. Depending on the laboratory size, employees could be more or less specialized.

Average Salary (per month) for a Clinical Research Associate may range from: US $4500-5000 In India, salaries may range between: INR 20,000-25,000 (or more, depending upon the experience and repute of the firm)

Average Salary (per month) for a Bioinformatics Specialist may range from: US $5000-6000 In India, salaries may range between: INR 30,000-45,000 (or more, depending upon the experience and repute of the firm)

Animal caretaker is nurturing animals used in biotech research. List of species used is long: all the way from mice and rats to cows and chimps. Water and food supplies, cage cleaning, animal health monitoring, relocation, milking, artificial insemination a lot of duties need to be performed and not all tasks are representative. If you put aside that animals have specific odor (and different bodily fluids and excretions) keep in mind that watching animal suffer during experiments isnt easy or nice thing to do. Average Salary (per month) for an Animal Caretaker may range from: US $1000-1200 In India, salaries may range between: INR 10,000-15,000

Average Salary (per month) for a Production Engineer may range from: US $6000-7000 In India, salaries may range between: INR 30,000-50,000 (depending upon experience, institute of study and company as well)

Average Salary (per month) for a QA engineer may range from: US $5000-6000 In India, salaries may range between: INR 25,000-30,000 (depending upon experience, institute of study and company as well)

Average Salary (per month) for a Consultant may range from: US $6000-8000 In India, salaries may range between: INR 30,000-1,00,000 (depending upon experience, institute of study and company as well)

Read the original post:
Careers in Biotechnology - List of various options

IMPACT FACTOR: 7.117 5-Year Impact Factor: 7.983 Issues per year: 6 issues Editorial Board

The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. In Current Opinion in Biotechnology, we help the reader by providing in a systematic manner: 1. The views of experts on current advances in biotechnology in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications.

Division of the subject into sections The subject of biotechnology is divided into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance.

Analytical biotechnology Plant biotechnology Food biotechnology Energy biotechnology Environmental biotechnology Systems biology Nanobiotechnology Tissue, cell and pathway engineering Chemical biotechnology Pharmaceutical biotechnology

Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments. This successful format has made Current Opinion in Biotechnology one of the most highly regarded and highly cited review journals in the field (Impact factor = 8.035).

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest

Read the original here:
Elsevier Current Opinion - Current Opinion in Biotechnology

Track-1: Industrial Biotechnology

Industrial biotechnology is one of the best encouraging new techniques to contamination evasion, asset protection, and cost lessening. It is much of the time said to as the third wave in biotechnology. On the off chance that created to its full forthcoming, mechanical biotechnology might have a higher impact on the World than human services and agrarian biotechnology. Mechanical biotechnology has molded proteins for use in our everyday lives and for the assembling division. Modern biotechnology organizations use numerous particular strategies to find and enhance nature's chemicals. Data from genomic concentrates on microorganisms is supporting specialists misuse on the abundance of hereditary differing qualities in microbial group.

Modern Biotechnology is a Multidisciplinary plan proposed to experience plant based biomass for the assembling of vitality and mass and claim to fame chemicals. "Open Innovation Cluster" for bioeconomy with consideration on mechanical biotechnology. It is anticipated that mechanical biotechnology will be continuously actualized by compound, pharmaceutical, sustenance, and farming commercial ventures.

The Global biotechnology market size was esteemed at USD 270.5 billion in 2013 and is required to develop at a CAGR of 12.3% inferable from the expanding interest for diagnostics and therapeutics arrangements. Rising government activities attributable to high importance towards development of the economy are relied upon to help the biotechnology market development over the gauge period.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-2: Bioprocess engineering

Bioprocess building is the adjustment or utilization of renewable constituents to create esteem included yields. It incorporates revelation, exploration, advance and the assembling and improvement of items. Bioprocess/biochemical/biotechnology/biotechnical building is a bureau of synthetic building, It decreases by the outline and development of types of gear and methods for the assembling of items, for example, agribusiness, nourishment, bolster, pharmaceuticals, nutraceuticals, chemicals, polymers then paper from living materials and examination of waste water.

Bioprocess Engineering, research accentuations on expansion of new biotechnological rehearses for creation of pharmaceuticals, solid nourishment components, mass chemicals and biofuels. Our experience is to create high esteem bio-based items in a legitimate and modest mode to stop decrease of regular assets and to expansion advancement of a bio-experimental industry.

Worldwide business sector for bioprocessing is reflecting the sensational development of the biotechnology business around the globe. Europe speaks to around 25% of Global business sector with 1,880 organizations with incomes roughly $13.5 billion.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-3: Industrial Fermentation

Fermentation process devours microorganisms to change strong or fluid substrates into different items. Aging determined items show gigantic quality. Mechanical aging is the planned utilization of maturation by organisms, for example, microbes other than growths to style items valuable to people. Matured items require order as sustenance and additionally in far reaching industry.

Some important chemicals, identical as acidic corrosive, citrus extract, in addition to ethanol are readied by aging. The proportion of aging relies on upon the compacting of organisms, cells, cell sections, and proteins furthermore temperature, pH and now vigorous aging Oxygen. Item recovery as often as possible embroils the assimilation of the weaken arrangement. Around all industrially fabricated catalysts, for example, lipase, invertase then rennet, are readied by maturation through hereditarily adjusted MI Fermentation process devours microorganisms to change strong or fluid substrates into different items. Aging inferred items show colossal quality. Mechanical aging is the purposeful utilization of aging by organisms, for example, microorganisms other than parasites to style items valuable to people. Aged items require demand as sustenance and in addition in far reaching industry.

Some significant chemicals, comparable as acidic corrosive, citrus extract, in addition to ethanol are readied by aging. The proportion of aging relies on upon the compacting of microorganisms, cells, cell sections, and compounds furthermore temperature, pH and now high-impact maturation Oxygen. Item recovery much of the time involves the ingestion of the weaken arrangement. Roughly all economically produced compounds, for example, lipase, invertase then rennet, are readied by aging through hereditarily altered microorganisms. In by and large, maturations can be separated into three sorts: Production of biomass, Production of extracellular metabolites, and Transformation of substrate.

Worldwide maturation chemicals market interest was 51.83 million tons in 2013. Expanding worldwide ethanol and methanol creation levels because of developing interest from liquor industry is likewise anticipated that would drive aging chemicals market. High assembling expense is likewise anticipated that would ruin the business sector development throughout the following six years.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Track-4: Microbial Biotechnology

Microorganisms have stayed persecuted for their unmistakable natural and physical properties from the beginning periods for heating, preparing, nourishment safeguarding and more as of late to manufacture anti-microbials, solvents, amino acids, bolster supplements, and engineered feedstuffs. Current advancements in Molecular Biology and hereditary building may offer novel elucidation to long-standing confusions. Over the wiped out decade, analysts have added to the practices to exchange a quality starting with one creature then onto the next, taking into account advancements of how microorganisms store, copy, and exchange inherited material.

As of late, aging procedures relied on upon uncommon sorts of crude materials and on accessible strains of microorganisms. Presently microorganisms can be hereditarily adjusted to capacity all the more advantageously and to hone a comprehensive assortment of substrates. As these microorganisms are re-built and their aging capacities completely persecuted, we expediently close to the day when substances can be delivered actually and financially.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-5: Fermentation Technology

Fermentation technology consolidate a wide field, yet inside this profile we focus on the utilization of organisms and proteins for development of intensifies that discover application in the vitality, substance, material, restorative and the sustenance portion. In spite of the fact that maturation hones have been utilized for eras, the need for biological generation of vitality and materials is testing creation and change of inventive aging hypotheses. Our efforts are coordinated both to the improvement of cell organizations and chemicals and also of configuration of novel practice ideas and advances for maturation routines.

Mechanical aging systems are progressively predominant, and are measured an essential innovative advantage for dropping our reliance on chemicals and items made from fossil energizes. Be that as it may, despite the fact that their expanding acknowledgment, maturation movements have not yet broadened the comparative advancement as conventional substance methodology, mostly when it emerges to utilizing building devices, for example, numerical representation and streamlining techniques.

Maturation innovation goal is to enhance aging systems for solutions e.g. anti-toxins, drug intermediates, chemicals, amino acids and different biotransformations.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-6: Biopharmaceuticals

Biopharmaceuticals may be made from microbial cells (recombinant E. coli or yeast societies), mammalian cell lines and plant cell societies and greenery plants in bioreactors of various designs, comprehensive of photograph bioreactors. Biopharmaceuticals can contain of proteins or extra sorts of items, for example, nucleic acids, viral quality treatment vectors , peptides, lipids and sugars, alone or in mix. The prevalence of biopharmaceuticals available these days are proteins, and in this way this idea concentrates on those activities required essentially for extension of protein-based therapeutics and wont make a difference to alternate classes of biopharmaceuticals.

In the course of recent years, rich new sorts of test biologic treatment have set up business enlistment, however the presence of bio-similarities means the greatest change in the biologic endorsement scene. The Bio pharmaceutics Classification System (BCS) is not just a significant device for picking up waivers vivo bioequivalence concentrates additionally for conclusion making in the advancement and early improvement of new medicines. Measurement of solvency and penetrability in the revelation/change foundations is depicted. The experimental premise and information necessities for dossiers at adjusted phases of advancement of biopharmaceuticals will be imparted for the perfection, preclinical and clinical parts of controlling entries.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track -7: Molecular Biotechnology

Molecular biotechnology is the act of research center techniques to ponder and in addition change proteins and nucleic acids for applications in ranges for example creature wellbeing and human wellbeing, the earth and Agriculture. Atomic biotechnology results from the joining of various scopes of exploration, for example, microbiology, sub-atomic science, immunology, natural chemistry, cell science and hereditary qualities. It is an elating field driven by the capacity to exchange hereditary material between life forms with the point of comprehension noteworthy organic movements or making a significant item. The end of the human genome venture has opened an innumerable of prospects to make new medications and medicines, and techniques to enhance current pharmaceuticals. Atomic biotechnology is a quickly changing and dynamic field. As the pace of advancements quickens, its centrality will rise. The unmistakable quality and impact of atomic biotechnology is being detected the country over.

The instruments of atomic biotechnology can be connected to enhance and grow, drugs , demonstrative tests, treatments, and antibodies that will expand creature and human wellbeing. Sub-atomic biotechnology has apparatus in creature and plant farming, Forestry, and nourishment preparing, Aquaculture, concoction and material assembling. Each normal for our lives in the up and coming times will be influenced by this dynamic stadium.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-8: Biofuels and Biorefinery

Biorefining commercial ventures produce heat, fuel, power and diverse chemicals. The items are readied from biomass, for example, backwoods based materials and sustenance waste. A bio refinery is an ability that acclimatizes biomass change forms and hardware to create heat, powers, control and esteem included chemicals from biomass, generation, new methodologies are in exploration and advancements are made each day. The bio-refinery model is like today's petroleum refinery, which yield different items and fills from petroleum. Feasible financial development requires safe assets for modern assembling, as bio refineries consolidates the fundamental advancements stuck between mechanical intermediates, bio-crude materials and last items.

Improvement and Research in ahead of schedule field of biorefinery are most extreme noticeable in United States, Europe (Kamm et al. 1998, 2000) to give no less than 25% natural carbon-based mechanical feedstock chemicals, 10%liquid fills from bio-based item industry. BCC Research assesses that the overall interest for bio items will ascend at a twofold digit compound yearly development extent (CAGR) of 12.6% over the accompanying five years to reach $700.7 billion in 2018 from $387.6 billion in 2013, when it will achieve a business sector scattering rate of 5.5% in 2018, from an anticipated rate of 4.2% in 2013. Blue Marble Energy, set up in 2007, is a U.S. based organization which misuses hybridized microbial relationship to create claim to fame renewable and biochemical biogas. Their organization operation is to dislodge oil with totally renewable, carbon impartial substitutes using nature-based elucidations.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-9: Genetically Modified Organisms

Late advancements in engineered science, the enthusiasm for hereditarily altered life forms (GMOs) is exponentially expanding and their applications for existent life show up adequately unending, going from the production of drugs and immunization to their utilization in the agro-nourishment field.

Many existing sensors, named cell-based bioassays and entire cell biosensors , have been in point of interest created in light of hereditarily adjusted cells, discovering applications in a few fields, running from natural checking to nourishment control, from criminological science to medication screening.

Absolutely this stances genuine administrative concerns and embodies a nonstop test for analysts, particularly concerning the potential spreading of GMOs into the earth. This GMO "duality" speaks to a captivating element and this Research Topic is planned to bear the cost of the analysts a look in this interesting field.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-10: Cell Culture

Cell society alludes to the expulsion of cells from a creature or plant and their consequent development in an ideal fake environment. The cells might be expelled from the tissue straightforwardly and disaggregated by enzymatic or mechanical means before development, or they might be gotten from a cell line or cell strain that has as of now been set up.

Critical development inside of the biopharmaceuticals business is impelling phenomenal advancement and interest for cell society items for the reasons of medication revelation and wellbeing testing. While 2D cell societies have been in research facility use following the 1950s, the business sector for 3D societies, which all the more precisely model human tissue in vivo without using creature test subjects, has seen fantastic development over the previous decade. Without a doubt, this business sector is ready to experience hazardous development inside of the figure period, and additionally make ripe ground for combinations, mergers, and acquisitions for some sorts and sizes of organizations.

Powered by poisonous quality testing and expanded biopharmaceutical creation, the test packs class is the speediest moving fragment of the general business sector, moving at a colossal 42% CAGR. Request here is driven by the way that test units contain all the important reagents and particular conventions bundled for research center use.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-11: Biomaterials

In the cutting edge society, because of advancements in innovation and industry, there are expanding instances of defunctionalisation or harm to tissues or organs from different mishaps, sicknesses, and maturing, and as the human body achieves its breaking points in self-recovery capacity, the requirement for appropriate and viable treatment strategies is expanding quickly. In like manner, studies on biomaterials valuable in tissue recovery are effectively being directed to outline materials that can actuate the recovery of the harmed tissue or organ. Examination is likewise right now being done on undifferentiated cell separation inside of platforms and instruments of the tissue recovery on transplant to the human body and endeavors on the improvement and use of its remedial system. Be that as it may, it is exceptionally hard to shape three-dimensional fake organ like the fundamentally complex tissue inside of the human body because of as far as possible in the biomaterial advancement.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-12: Enzymes from Extreme Environments

Enzymes are nature's biocatalysts engaged with high synergist power and noteworthy substrate specificity. Catalysts perform an extensive variety of capacities all through nature, and guide the organic chemistry of existence with awesome exactness. The lion's share of proteins perform under conditions considered ordinary for mesophilic, neutrophilic, physical microorganisms. Notwithstanding, the Earth's biosphere contains a few districts that are amazing in examination, for example, hypersaline lakes and pools, aqueous vents, chilly seas, dry deserts and regions presented to concentrated radiation. These zones are possessed by a substantial number of extremophilic microorganisms which create compounds equipped for working in bizarre conditions.

There is an expanding biotechnological and modern interest for catalysts steady and working in cruel conditions, and over the previous decade screening for, disconnection and generation of chemicals with one of a kind and amazing properties has gotten to be one of the preeminent ranges of biotechnology examination. The improvement of cutting edge sub-atomic science apparatuses has encouraged the journey for creation of chemicals with streamlined and amazing components. These instruments incorporate expansive scale screening for potential qualities utilizing metagenomics, building of chemicals utilizing computational strategies and site-coordinated mutagenesis and atomic advancement methods.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-13: Agriculture Biotechnology

Late advances in rural biotechnology have empowered the field of plant science to advance in extraordinary a wide margin. plant genomics and crop science have realized an outlook change of thought with respect to the way by which plants can be used both in agribusiness and in drug. Other than the all the more understood upgrades in agronomic attributes of harvests, for example, ailment resistance and dry spell resilience, plants can now be connected with points as different as biofuel generation, phytoremediation, the change of nourishing qualities in consumable plants, the recognizable proof of mixes for restorative purposes in plants and the utilization of plants as remedial protein creation stages. This expansion of plant science has been joined by the colossal plenitude of new licenses issued in these fields and, the same number of these developments approach business acknowledgment, the consequent increment in horticulturally based commercial enterprises. While this survey part is composed principally for plant researchers who have awesome enthusiasm for the new headings being brought regarding applications in farming biotechnology, those in different orders, for example, therapeutic specialists, ecological researchers and designers, might discover critical worth in perusing this article too.

The survey endeavors to give a review of the latest licenses issued for plant biotechnology concerning both farming and drug. The section finishes up with the suggestion that the consolidated main impetuses of environmental change, and additionally the regularly expanding requirements for clean vitality and nourishment security will assume a urgent part in driving the course for connected plant biotechnology research later on.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-14: Biotechnology Market

The development of Biotechnology industry according to Transparency Market Research is evaluated to watch significant development amid 2010 and 2017 as ventures from around the globe are expected to rise, particularly from rising temperate districts of the world. The report expresses that the worldwide business sector for biotechnology, concentrated on as per its application ranges, might develop at a normal yearly development rate of CAGR 11.6% from 2012 to 2017 and achieves a quality worth USD 414.5 billion before the end of 2017. This business sector was esteemed roughly USD 216.5 billion in 2011. The business sector of bio agriculture, consolidated with that of bio seeds, is anticipated to achieve a quality worth USD 27.46 billion by 2018. The field of biopharmaceuticals ruled the worldwide biotechnology advertise and represented 60% shares of it in the year 2011. Numerous biotechnological commercial ventures prospered by the innovative progressions prompting new revelations and rising requests from the pharmaceutical and farming parts.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-15: Global Bioeconomy

The Bioeconomy envelops the generation of renewable natural assets and their change into nourishment, bolster, bio-based items and bioenergy through creative and productive advancements gave by Industrial Biotechnology. It is now a reality and one that offers extraordinary open doors and answers for a developing number of major societal, natural and monetary difficulties, including environmental change moderation, vitality and sustenance security and asset effectiveness. The objective is a more creative and low-outflows economy, accommodating requests for maintainable farming and fisheries, nourishment security, and the reasonable utilization of renewable organic assets for modern purposes, while guaranteeing biodiversity and ecological insurance.

A definitive point of the bioeconomy is to keep Europe focused, imaginative and prosperous by giving practical, keen and comprehensive monetary development and employments, and by addressing the necessities of a developing populace whilst securing our surroundings and resources.Europe is a pioneer in the improvement of the bioeconomy, yet rivalry and enthusiasm for this field keeps on developing the world over.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Related Conferences

6thWorld Congress onBiotechnology, October 05-07, 2016, New Delhi India; 10thAsia PacificBiotechCongress July 25-27, 2016, Bangkok, Thailand; 11thEuro BiotechnologyCongress, November 07-09,2016, Alicante Spain; 12thBiotechnologyCongress, Nov 14-15, 2016, San Francisco, USA; BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBiobased Chemicals:Commercialization&Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnologyand theBioeconomy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnologyWorld Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess EngineeringandTechnology, 20th to 22nd January 2016,Kolkata, India; Global BiotechnologyCongress 2016, May 11th - 14th 2016, Boston, MA, USA

Track-16: New Biomedical device

The part of restorative gadgets in social insurance is fundamental. A restorative gadget is an instrument, contraption, insert, in vitro reagent, or comparative that is utilized to analyze, avoid, or treat sickness or different conditions. This classification incorporates news on item reviews, item wellbeing, inserts and prosthetics, new innovative improvements, automated surgery, restorative gadgets for use by therapeutic experts or patients.

Biomechanical designing is the consolidated utilization of mechanical building principals and natural information to better see how these territories cross and how they can be utilized together to possibly enhance people groups' personal satisfaction. Biomechanics research in the office centers upon mechanics at the cell, tissue, and joint level with applications in orthopedics and musculoskeletal and cardiovascular frameworks. Bioengineering offers a multi-disciplinary, cross-collaborative program that is focused on a new view of human health and disease. Biomedical Engineering (BME) is the application of engineering principles and design concepts to medicine and biology for healthcare purposes (e.g. diagnostic or therapeutic). This field seeks to close the gap between engineering and medicine. Biomedical engineering has only recently emerged as its own study, compared to many other engineering fields. Such an evolution is common as a new field transitions from being an interdisciplinary specialization among already-established fields, to being considered a field in itself.

Related Biotechnology Conferences | Industrial Biotechnology Events | Bioeconomy Congress

Read the original:
Biotechnology Conferences| Industrial Biotechnology Events ...

SIGN UP TODAY FOR OUR NEXT INFO SESSION!

Palm Beach State College offers two degree programs in biotechnology. Students may choose to enroll inthe Associate in Science (AS) degree, which prepares students for entry into the biotechnology workforce, academic research, and related industries; or a dual Associate in Arts (AA)/(AS) degree option, designed for pre-med and other students planning to transfer to a four-year university. Both the AS and dual AA/AS programs require students to complete a 4-month Biotech internship outside of the College that provides training in real-world academic or industry research.

Our award winning program is taught byPhD level scientific faculty and researchers committed to providing challenging courses to meet the needs of the growing biotech industry.

We also offera 19-credit Biotechnology College Credit Certificate (CCC) for studentswho already have a bachelor's degree and want to gain the in-demand skills employers require and the internship needed to get a high-tech job orto strengthen anapplication to graduate or medical school.

Palm Beach State's biotech business partnership, consisting of over 25 different biotech firms, allows our students unique internship opportunities which develop the skills and experience required for a successful career in the biotechnology field.

Information for Advisors and Prospective Students

To get started in our Biotechnology program or foradditional information pleasecontact:

Read this article:
Palm Beach State - Biotechnology

Latest Articles

Efforts to expand use of biotechnology to crops other than corn, soybeans, cotton and canola have been hindered by opposition from consumer and environmental groups.

By ANDREW POLLACK

Federal officials have approved a cheaper version of Johnson & Johnsons blockbuster drug Remicade, a biotech medicine for inflammatory diseases.

General Mills said on Friday that it would start labeling all products that contain genetically modified ingredients to comply with a law set to go into effect in Vermont.

The salary, bonus and stock awards given to Fords chief executive, Mark Fields, jumped 17 percent in 2015.

The senators will consider whether the government should require labeling on foods containing genetically engineered ingredients, an issue that has split the food industry.

By JENNIFER STEINHAUER and STEPHANIE STROM

A diverse biotechnology company hopes its genetically engineered mosquitoes can help stop the spread of a devastating virus. But thats just a start.

By ANDREW POLLACK

States should be free to require the labeling of genetically modified food if they want to.

By THE EDITORIAL BOARD

Bioengineers at Rice University recently found that different drops from single fingerpricks on multiple subjects varied substantially.

By DONALD G. McNEIL Jr.

With the success of growing the body parts in a lab, bioengineers are taking a step toward creating replacement organs that can be transplanted into people.

By NICHOLAS ST. FLEUR

Marc Tessier-Lavigne, who will leave Rockefeller University to lead Stanford University, has also worked as an executive in the biotech industry,

The two biotech companies initial public offerings are testing the waters after a recent sell-off in biotech.

Businesses allow parents to leverage their wealth, contacts and the hope of investors to jump-start research into the diseases that afflict their children.

By PAUL SULLIVAN

Scientists have shown that DNA molecules can be the basis for a long-term storage system potentially capable of holding all of the worlds digital information in a tiny space.

By JOHN MARKOFF

The herbicide, which contains the old herbicide 2,4-D, was to be used on crops genetically modified to be resistant to it.

The Food and Drug Administration said that the salmon would not have to be labeled as genetically engineered, consistent with its broader stance on widely eaten genetically modified foods.

Senator Orrin G. Hatch objects to language that would limit brand-name drug makers monopoly protections abroad for their cutting-edge medicines known as biologics.

By JACKIE CALMES

The case is significant because it indicates that cell therapies might not have to be customized for each patient.

By ANDREW POLLACK

An irrational phobia of genetically modified crops is causing real harm.

By MARK LYNAS

A confluence of factors, including Chinas slowing growth, falling commodity prices and trouble in the biotech sector, sent the markets lower.

Readers explain why they disagree with Dr. Ezekiel J. Emanuels proposed solutions for rising drugs costs.

Efforts to expand use of biotechnology to crops other than corn, soybeans, cotton and canola have been hindered by opposition from consumer and environmental groups.

By ANDREW POLLACK

Federal officials have approved a cheaper version of Johnson & Johnsons blockbuster drug Remicade, a biotech medicine for inflammatory diseases.

General Mills said on Friday that it would start labeling all products that contain genetically modified ingredients to comply with a law set to go into effect in Vermont.

The salary, bonus and stock awards given to Fords chief executive, Mark Fields, jumped 17 percent in 2015.

The senators will consider whether the government should require labeling on foods containing genetically engineered ingredients, an issue that has split the food industry.

By JENNIFER STEINHAUER and STEPHANIE STROM

A diverse biotechnology company hopes its genetically engineered mosquitoes can help stop the spread of a devastating virus. But thats just a start.

By ANDREW POLLACK

States should be free to require the labeling of genetically modified food if they want to.

By THE EDITORIAL BOARD

Bioengineers at Rice University recently found that different drops from single fingerpricks on multiple subjects varied substantially.

By DONALD G. McNEIL Jr.

With the success of growing the body parts in a lab, bioengineers are taking a step toward creating replacement organs that can be transplanted into people.

By NICHOLAS ST. FLEUR

Marc Tessier-Lavigne, who will leave Rockefeller University to lead Stanford University, has also worked as an executive in the biotech industry,

The two biotech companies initial public offerings are testing the waters after a recent sell-off in biotech.

Businesses allow parents to leverage their wealth, contacts and the hope of investors to jump-start research into the diseases that afflict their children.

By PAUL SULLIVAN

Scientists have shown that DNA molecules can be the basis for a long-term storage system potentially capable of holding all of the worlds digital information in a tiny space.

By JOHN MARKOFF

The herbicide, which contains the old herbicide 2,4-D, was to be used on crops genetically modified to be resistant to it.

The Food and Drug Administration said that the salmon would not have to be labeled as genetically engineered, consistent with its broader stance on widely eaten genetically modified foods.

Senator Orrin G. Hatch objects to language that would limit brand-name drug makers monopoly protections abroad for their cutting-edge medicines known as biologics.

By JACKIE CALMES

The case is significant because it indicates that cell therapies might not have to be customized for each patient.

By ANDREW POLLACK

An irrational phobia of genetically modified crops is causing real harm.

By MARK LYNAS

A confluence of factors, including Chinas slowing growth, falling commodity prices and trouble in the biotech sector, sent the markets lower.

Readers explain why they disagree with Dr. Ezekiel J. Emanuels proposed solutions for rising drugs costs.

See the original post:
Biotechnology - The New York Times

Biotechnology: One of the Bay Area's Top Growth Industries

The Bay Area is a leader in the global biopharmaceutical industry, with local companies and research institutions setting the pace in the discovery and development of biopharmaceuticals to target major unmet medical conditions, such as cardiovascular disease, cancer, AIDS and other degenerative diseases.

UCSC Extensions Biotechnology Certificate provides a solid understanding of the scientific disciplines that underlie the industrys activities, a foundation in the principles that guide drug discovery and development, an appreciation of cutting-edge bioscience research and technology, and a broader awareness of todays biopharmaceutical industry. This combination of general and practical knowledge enhances the skills of professionals currently working in this industry and helps prepare others to enter this dynamic field.

This program is designed for chemists, biologists and other scientists who want to enhance their knowledge of the principles and applications of biotechnology. It also benefits individuals from other disciplines who need a solid scientific foundation in order to enter or work more effectively in the biopharmaceutical field.

Continued here:
Biotechnology | UCSC Extension Silicon Valley

Home Academics College of Science and Mathematics Biology Department Graduate Programs Biotechnology, MS

Degree Requirements | Admission Requirements | Transfer Credit Policy | Costs and Financial Aid

This MS program in biotechnology and biomedical science trains students in the theory and laboratory techniques used in biotechnology and biomedical science-two high technology areas of expanding national and local importance. The program provides a firm foundation in the principles underlying modern biotechnology techniques, and integrates this theoretical understanding with intensive training in a variety of laboratory skills and in computer applications to biotechnology.

The curriculum of the program consists of required courses in biology and biophysics, a required two-semester research experimentation course, and elective courses in biology, chemistry, and physics. Work in these courses is particularly appropriate for students with interests in the emerging fields of biotechnology, molecular genetics, tissue culture, and computerized laboratory technology.

Thirty credits are required for the master of science degree in biotechnology and biomedical science.

Each degree candidate is assigned to a three-member advising committee, which will be responsible for insuring that the student fulfills all requirements of the program and the Office of Graduate Studies.

All students must complete the following courses for a total of 9 credits:

All students must complete at least four of the following courses for a minimum of 12 credits:

Students must complete the remainder of credits (9 credits) by taking elective courses chosen from the following list. At least two must be biology courses.

Students wishing to substitute any other courses for those on this list of electives must have prior approval from their Academic Advising Committee and the graduate program director in biology.

Each student prepares a written report on his or her research work and must also take an oral examination, which will not necessarily be limited to the topic of the report. The student must submit an outline of the report to his or her advising committee before taking the oral examination.

Students may choose either an internship option or a thesis option, which will enable them to pursue a thesis research project in the laboratory of a faculty member. Thesis students have the option of taking 4 additional research credits, as Biol 699. This, in combination with two semesters of Biol 696, will allow for a maximum of 10 credits toward research.

Note: These degree requirements are subject to change as developments in the field affect the program's curriculum. Please contact the director of graduate programs in biology for the most current information.

Test of English as a Foreign Language (TOEFL official test score) is required for international applicants. For more information regarding minimal TOEFL scores go to Graduate Admissions. The stated interests of a prospective student must coincide to an acceptable degree with the faculty specialties represented in the program. The Biology Graduate Committee in conjunction with the Director of Graduate Programs in Biology is responsible for reviewing applications and for recommending candidates to the dean of graduate studies.

Applicants who have completed appropriate graduate course work at other accredited institutions may transfer the equivalent of six credits toward UMass Boston graduate degree requirements from courses in which the applicant received a grade of B or higher, provided these are courses that have not been used to fulfill requirements for another degree,andwere completed no more than seven years before the applicant's matriculation of UMass Boston.Transfer credit is subject to the final approval of the graduate program director and the dean of graduate studies.

As a public university, the costs of attending UMass Boston are moderate, especially for students who qualify as residents of Massachusetts. Financial aid is available in the form of grants, loans, and a limited number of assistantships that provide a stipend and remission of tuition.

For information about financial assistance please see the graduate assistance page, or write or call:

Office of Financial Aid Services University of Massachusetts Boston 100 Morrissey Blvd. Boston, MA 02125 617.287.6300

Please consult the frequently asked questions (FAQs) at the bottom of the preceding Graduate Programs home page.

Faculty in the School for the Environment and Computer Science and Chemistry Departments also participate in this program.

Please note: All information on this website is subject to change. This website is neither a contract nor an offer to make a contract.

See the article here:
Biotechnology, MS - University of Massachusetts Boston

The Bachelor of Science in Biotechnology program trains students in many disciplines including genetics, biochemistry and molecular biology and prepares them for entry into health sciences and analytical / research laboratories. Graduates possess the skills to perform laboratory tests using standardized laboratory procedures.

Graduates of the program will have completed the prerequisites necessary to be successful in graduate programs in the sciences. However, a Bachelor of Science in Biotechnology can also be a terminal program for individuals who wish to work in laboratory settings and other occupations.

The following objectives are designed to meet Keiser Universitys mission and its objectives.

To receive a Bachelor of Science in Biotechnology, students must earn 129 credit hours. Program requirements are as follows:

Lower Division General Education Courses( 31.0 credit hours )

Note: To view the PDF file linked above you will need to have Adobe Reader. To download a free copy of this software click here or go to the Adobe website at http://www.adobe.com.

See the rest here:
Biotechnology, BS - Keiser University

They employ biochemical, moleculobiological; and genetic methods alongside methods of engineering. The tasks of biotechnologists include the utilization of cell culture techniques, the operation of bioreactors, and the development of biotechnological procedures. They moreover convert methods developed in the laboratory into full-scale engineering operations, take full responsibility for the smooth running of production processes, or conceptualize and supervise bioprocess engineering systems Structure 1st 3rd semester: Core curriculum 4th semester: Master thesis and final exams Time model Full-time Academic year Winter semester: October January Summer semester: March June Contents Biotechnology (47%) Current Industrial Projects (12,5%) Scientific Methods & Master Thesis (33%) General Management (7,5%) Admission requirements Graduates of relevant Bachelor programs Graduates of post secondary courses pertaining to the intended studies (i.e. process engineering, chemical engineering, biological engineering, biotechnology) Selection process Career background (30%) Written exam (20%) Interview (50%) Application Online. Please consider the indicated deadlines Contact MCI MANAGEMENT CENTER INNSBRUCK The Entrepreneurial School Biotechnology Maximilianstrae 2 A-6020 Innsbruck/Austria +43 512 2070-3800, This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post here:
Biotechnology - MCI Management Center Innsbruck

The work of the Biology and Biotechnology Department at WPI goes far beyond the theoretical. Students, faculty, and industry collaborate in research and discovery to solve problems that affect us all. Their goals: to help treat and cure common, dread diseases, like Alzheimers and cancer; heal wounds faster; create a greener world through science; and use computer science techniques to solve flesh-and-blood problems.

And weve only scratched the surface of what the Biology and Biotechnology Department is doing. Its state-of-the-art new research center, the Life Sciences and Bioengineering Center at Gateway Park, is practically bursting at the seams with fundamental and applied research, conducted with cutting-edge instrumentation and tools. Here, graduate and select undergraduate students work across disciplines and with companies in the field.

Graduates of the Biology and Biotechnology Department at WPI go on to myriad careers in industry and academia, across organizations large and small. And the research interests of our faculty encompass a similarly large range.

Its an exciting time for the life sciences. We invite you to learn more about how the Biology and Biotechnology Department can help you reach your educational and career goals.

Assistant Professor Luis Vidali describes his collaboration with Assistant Professor Erkan Tuzel of the Department of Physics to investigate cell biology and help develop a more active biophysics program at WPI.

Follow this link:
Biology & Biotechnology - WPI

STATEMENT OF INTEREST OF AMICUS CURIAE

The Biotechnology Industry Organization (BIO) is the world's largest biotechnology trade association, providing advocacy, development, and communications services for over 1,100 members worldwide. BIO members - many of whom are small, emerging companies-involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.

BIO has no direct stake in the result of this appeal, nor does BIO take a position on the ultimate validity or infringement of the claims to a method of obtaining viable hepatocytes for medical uses. No counsel for a party authored this brief in whole or in part, and no such counsel or party, nor any person other than the amicus curiae or its counsel, made a monetary contribution intended to fund the preparation or submission of this brief. This brief is solely the work of BIO and its counsel and reflects BIO's consensus view, but not necessarily the view of any individual member or client. BIO and its members are concerned that the development and commercialization of a diverse array of biotechnologies, including diagnostic testing and personalized medicine, will be hampered, if not precluded, if this Court does not address the mounting uncertainty currently afflicting patentable subject matter jurisprudence.

Unfortunately, the District Courts decision has done nothing to alleviate that uncertainty, but instead has exacerbated doubts as to whether meaningful patent protection remains available in the United States for many biotechnology inventions, and if so, the extent of that protection and the means to draft commercially meaningful method claims that meet the newly heightened standard for patent eligibility. The invention in this case would traditionally have been deemed eligible subject matter for patenting under 35 U.S.C. 101. It provides an excellent opportunity for the court to provide timely clarification on issues of critical concern to BIO and its members.

Excerpt from:
Brief of the Biotechnology Industry Organization as Amicus ...

Federal Activities Report on the Bioeconomy page cover

5/4/2016 UPDATE:

Bioeconomy Webinar Information: Thursday, May 5, 2 p.m.4 p.m. Eastern Time Session Link: https://thinktank.inl.gov/login.html?sessionID=59 Session Passkey: 123 Call in: +1 (562) 247-8422 Access Code: 287-084-886

The USDA and other federal agencies recently released the Federal Activities Report on the Bioeconomy (FARB) documenting federal agency activities aimed at helping to develop and support the bioeconomy an emergingpart of the overall U.S. economy. Emphasis is specifically placed on the production and use of biofuels, bioproducts, and biopower. USDA Chief Scientist and Under Secretary for Research, Education, and Economics (REE), Dr. Catherine Woteki, stresses these fuels, power, and products are produced using biomassagricultural residues, grasses, energy crops, forestry trimmings, algae, and other sourcesinstead of fossil fuels.

The report also delves into the Billion Ton Bioeconomy Vision, an effort coordinated through the Biomass Research and Development (R&D) Board. Comprised of industry experts from the Departments of Energy (DOE), Agriculture (USDA), Interior (DOI), Transportation (DOT), Defense (DoD), and the Environmental Protection Agency (EPA), the National Science Foundation (NSF), and the Office of Science and Technology Policy (OSTP), the Board is committed to collaboration among federal agencies on bioeconomy conceptions working to triple the size of todays bioeconomy by 2030to more than a billion tons of biomass. Read more

Tags: bioeconomy, biofuels, Biomass, BioPreferred, Biotechnology, California, Department of Defense, Department of Energy, Department of Interior, Department of Transportation, Dr. Catherine Woteki, Harry Baumes, National Science Foundation, OCE, REE, U.S. Environmental Protection Agency, White House

Economic Growth, Energy

Innovation, biotechnology and big data are changing the way we produce, distribute and even consume food. From using innovative approaches to improve food safety to sharing market data to assist producers in reaching larger markets, big data and new technologies continue to change the face of agriculture. USDA strives to meet these evolving challenges and will be discussing these issues through the lens of agriculture at the 2015 Agricultural Outlook Forum on Feb. 19-20 in Arlington, Virginia.

Big data isnt just massive amounts of numbers and codes for scientists, researchers and marketers. That information, when interpreted and applied, can help people understand and change the world around them. We are discussing how data helps producers of agricultural commodities in adapting their strategies to meet changing consumer demands, marketing practices and technologies. Read more

Organic meat and poultry producers can now use a streamlined process to get approval for labels verifying that their products do not include genetically engineered (GE) ingredients.

USDAs Food Safety and Inspection Service (FSIS) released new procedures for including a non-genetically engineered statement on the label of organic meat and poultry products. This is consistent with organic regulations, which have always prohibited the use of GE in all organic products. Now, with the new process, it will be easier for certified organic entities to add these claims to existing FSIS-approved products, speeding up the label review process. Read more

Tags: AMS, Biotechnology, Farmers, Food Safety, FSIS, genetic engineering, GMO, Meat and Poultry, National Organic Program, NOP, NRCS, organic, Organic 101, organic certification, Poultry, Tom Vilsack

Food Safety

Emmanuel Amoakwah, a Borlaug Fellow from Ghana currently studying at Ohio State University, gives a presentation on climate change during the Borlaug Symposium at the 2013 World Food Prize on Oct. 16. Approximately 40 Borlaug Fellows and their mentors attended the annual event in Des Moines to network, meet members of the Borlaug family and high-level agricultural officials and this years World Food Prize Laureates. (Photo by Jared Henderson, University of Missouri)

Every year the World Food Prize recognizes the achievements of individuals who have advanced human development by improving the quality, quantity or availability of food in the world. Nobel Peace Prize Laureate Dr. Norman E. Borlaug created the prize, which emphasizes the importance of a nutritious and sustainable food supply for all people.

This years event was held from Oct. 16-19 in Des Moines, Iowa, and also included a USDA-sponsored symposium for 40 foreign scientists from 23 countries (and their university mentors) in the Foreign Agricultural Service Borlaug Fellowship Program. Since 2004, the program has provided U.S.-based training and collaborative research opportunity for scientists and policymakers from developing and middle-income countries to promote food security and economic growth. Read more

Tags: Biotechnology, Borlaug Fellowship Program, Climate Change, coffee, Economic Growth, FAS, food insecurity, Food Security, Iowa, Kenya, Norman Borlaug, Science, Tennessee, World Food Prize

Food and Nutrition, Food Security

Sec. Tom Vilsack visited the grain grading laboratory of GIPSA's Board of Appeals and Review (BAR) and the Grading Service Laboratory (GSL) on October 23, 2013. BAR staff explain their grading review process while BAR Chairman Jim Whalen looks on.

The Grain Inspection, Packers and Stockyards Administrations (GIPSA) National Grain Center (NGC) was proud to host Agriculture Secretary Tom Vilsack on Wednesday, October 23. The NGC, located in Kansas City, MO, is home to the Federal Grain Inspection Services (FGIS) Technology and Science Division along with staff from FGIS Quality Assurance and Compliance Division and Field Management Division.

The grain inspectors, scientists and engineers at the NGC provide a broad spectrum of grain inspection services and support within recently renovated state of the art laboratories. During the visit, NGC staff demonstrated how they oversee, develop and approve methods and instruments used for grain inspection that ensure the consistent standard of measuring quality essential to grain marketing. Read more

On Friday, May 17, 2013, in Mexico City, Mexico USDA Secretary Tom Vilsack led U.S. and Mexican agribusiness representatives in a discussion of priority issues affecting North American agriculture. The roundtables participants represented the breadth and diversity of agricultural trade between the United States and Mexico. Representatives from Grupo Bimbo, Gruma, Driscolls, Cargill, and others joined the Secretary, U.S. Ambassador to Mexico Anthony Wayne, and Acting Deputy Under Secretaries Suzanne Heinen and Max Holtzman to share their views on the opportunities and obstacles facing increased agricultural trade between the United States and Mexico. Read more

Tags: Biotechnology, Climate Change, ethanol, Farm Bill, Food Farm and Jobs Bill, Food Safety, immigration, Mexico, Renewable Energy, Suzanne Heinen, Tom Vilsack

Climate Change, Trade

Original post:
USDA Blog Biotechnology

PROGRAM DESCRIPTION

The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.

The Master of Science in Biotechnology program in the College of Medicine will prepare students to function in the industrial biotechnology environment. This program is designed to give students broad knowledge and training in the scientific and practical aspects of biotechnology.

It involves innovative, hands-on and multidisciplinary learning approaches to educate and train students in scientific aspects of biotechnology. The courses and research training required of all students in this program are designed to develop independent thinking, team work and communication skills, which are highly desirable in the biotechnology industry. Students will be provided an industrial perspective and an understanding of product development at the same time as they are trained in the biotechnology techniques required for such development.

The Master of Science in Biotechnology program consists of a minimum of 30 semester credit hours of graduate courses offeredby the Burnett School of Biomedical Sciences inthe College of Medicine that includes 21 credit hours minimum of required courses, 3 credits of restricted electives,and 6 credit hours of thesis research as detailed below.

What makes this program unique is the focus on practical training offered to graduate students through masters thesis research in molecular biotechnology to perform jobs in laboratory environment that require scientific talent.

Students must take the following courses plus at least two credit hours of graduate seminar.

MCB 5722C Methods in Biotechnology (4 credit hours) or BSC 6407C Laboratory Methods in Molecular Biology (3 credit hours)

BSC 6432 Structure-Function-Relationships of Biomedical Sciences I (5 credit hours)

BSC 6433 Structure-Function-Relationships of Biomedical Sciences II (5 credit hours)

BSC 6431 Practice of Biomedical Sciences (3 credit hours)

PCB 5527 Genetic Engineering and Biotechnology (3 credit hours) or one of the following: BSC 5418 Tissue Engineering (3 credit hours), MCB 6417C Microbial Metabolism (3 credit hours), PCB 5025 Molecular and Cellular Pharmacology (3 credit hours)

Students will participate in at least two graduate seminar courses thatwill prepare them for making professional presentations with emphasis in biotechnology. The courseswill involve participation of speakers from the biotechnology industry with emphasis on an industrial perspective on biotechnology applications and product development.

Students willselect three credit hours of restricted electives from the list below.

Students will take a minimum of six credits of thesis research (MCB 6971) to complete their research and submit their thesis specializing in biotechnology research. Students are expected to have an in-depth discussion with at least three faculty members before choosing alaboratory for thesis research.The student and the Thesis Adviser/Major Professor will jointly recommend an advisory committee comprised of at least three members. The committee composition must reflect expertise relevant to the students thesis research and must be approved by the Graduate Committee. Students switching to change the composition of the Thesis Advisory Committee must also obtain approval from the Graduate Committee.

The thesis proposal defense requirement should be met and passed successfully no later than the end of the summer of the first year in the program. Students will not be allowed to register for courses for the Fall semester of their second year until this requirement is fulfilled. The Thesis Proposal requirement includes: 1) a written 5-page thesis proposal; 2) a thesis proposal defense in front of the thesis committee; and 3) questions by the thesis committee to test the student's understanding of the basic concepts in the field and relevant applications. The student will be evaluated on performance in all three sections. Should the student fail, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from the program.

An oral thesis defense is required. The defense will be in the format of:

A 50-minute presentation of the thesis work, including a 5-minute introduction

A 10-minute free period for the general audience to ask questions

A 1-hour closed-door examination by the Thesis Advisory Committee and the program faculty present

The thesis should be of significant scope and depth such that the work has made advances in the area of biotechnology. The MS thesis research must generate sufficient quantity and quality data to support the submission of a minimum of one manuscript. Approval of the final thesis will require consent from the majority of the Program Faculty who choose to review the thesis, inclusive of the Thesis Advisory Committee. Faculty members with dissenting vote on the thesis must provide written justification. Scientific journal review criteria will be used as guidelines by the faculty to evaluate the final thesis for its appropriateness for publication in the target journal.

Students will be evaluated on the progress in thesis research by the thesis advisory committee for fall and spring. Two consecutive unsatisfactory evaluations will result in dismissal from the program.

Students must pass a comprehensive exam to qualify for the Master of Science degree.

Students must successfully pass an oral comprehensive examination to test the understanding of the basic concepts in the field and relevant applications. The Comprehensive Examination will be conducted during the thesis proposal defense.The exam will be administered by the thesis committee. Should the student fail this exam, a second opportunity will be provided within 2 weeks of the first attempt. A second failure will result in dismissal from theprogram.

For information on general UCF graduate admissions requirements that apply to all prospective students, please visit theAdmissions section of the Graduate Catalog.Applicants mustapply online. All requested materials must be submitted by the establisheddeadline.

In addition to thegeneral UCF graduateapplication requirements, applicants to this program must provide:

Personal interviews are helpful but not required. Applicants whodo not have a competitiveGPA or GRE may occasionally be accepted if there is other convincing evidence of potential for high achievement and success.

Applicants who hold a BS degree in unrelated fields are expected to have the equivalent of 16 semester hours of credit in the biotechnology/biological sciences including a course in general microbiology, biochemistry or molecular biology or cell biology, plus one year of organic chemistry, one year of physics, basic university mathematics and statistics, and laboratory skills equivalent to the minimum required of our own undergraduates. Minor deficiencies may be remedied after acceptance by enrollment at the first opportunity in an appropriate course.

-

-

-

-

-

-

Fellowships are awarded based on academic merit to highly qualified students. They are paid to students through the Office of Student Financial Assistance, based on instructions provided by the College of Graduate Studies. Fellowships are given to support a students graduate study and do not have a work obligation. For more information, see UCF Graduate Fellowships, whichincludes descriptions of university fellowshipsand what you should do to be considered for a fellowship.

Read more:
Biotechnology MS Degree - UCF Graduate Catalog 2016-2017

Prepare for a cutting-edge career with a bachelor's degree in biological sciences from Miami Dade College. South Florida is home to two major life sciences research hubs and more than 1,300 companies that are creating the future right now and have a high demand for skilled workers. This program responds to the needs of our regions employers.

A capstone internship with a prospective employer or private/public partner moves beyond the classroom, allowing you to put your skills to the test in the real world.

The biotechnology concentration of this bachelors program helps you build the knowledge and skills youll need to succeed in the life sciences. As a biotechnology student, youll learn about:

Continued growth in the biotechnology and medical research fields is expected to continue to drive growth in the life sciences industry, especially in the South Florida region, which is rapidly evolving into a hot spot for life sciences research. An education in biotechnology opens doors to careers in a variety of workplaces, including:

These four-year programs combine extensive academic studies with the real-world experience students need to pursue a career in their selected field.

Continue reading here:
Biotechnology - Miami Dade College

More On This Industry Summary News Leaders & Laggards Company Index Industry Browser Related Industries Diagnostic Substances Drug Delivery Drug Manufacturers - Major Drug Manufacturers - Other Drug Related Products Drugs - Generic Top Industries Auto Manufacturers - Major Biotechnology Business Software & Services Chemicals - Major Diversified Communication Equipment Conglomerates Diversified Computer Systems Diversified Investments Diversified Utilities Drug Manufacturers - Major Electric Utilities Food - Major Diversified Industrial Metals & Minerals Major Airlines Major Integrated Oil & Gas Money Center Banks Property & Casualty Insurance Semiconductor - Broad Line Telecom Services - Domestic Tobacco Products, Other Complete Industry List... In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report. Industry Market Summary Biotechnology Composite Value:918.9 Today's Change:-0.68% S&P 500: -0.29% Biotechnology News Stemline Therapeutics SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds Sat 7:07 pm ET (GlobeNewswire) NEW YORK, June 04, 2016-- Stemline Therapeutics, Inc. announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid ... TESARO Provides Pipeline Update at ASCO Investor Briefing - (GlobeNewswire) Data Presented at ASCO 2016 Builds upon Foundation of Abraxane Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer - (Business Wire) More News on Biotechnology: Latest News, Industry Top Performers Intraday Price Performance % Change Market Cap More Top Intraday Price Performers... Market Capitalization % Change Market Cap SHIRE [SHP.L] -0.94% $2607.6 B AMGEN [AMGN.MX] -0.52% $2216.5 B GILEAD SCIENCES [GILD.MX] -0.62% $2134.9 B SUN PHARMACEUTICALS INDUSTRIES [SUNPHARMA.NS] -1.26% $1831.4 B AMGEN-T [4332.HK] 0.00% $505.0 B More Top Companies by Market Cap... More Top Performers: by Valuation, by Growth, by Financial Strength Industry Calendar Upcoming Events Date Co Event 06/05/16 EXEL Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 06/06/16 ARIA ARIAD Pharmaceuticals Investor and Analyst Briefing and Webcast 06/11/16 AGIO Agios Pharmaceuticals Inc Conference Call to Discuss Data from PKR Activators AG-348 and AG-519 More Upcoming Events... Recent Events Date Co Event 06/03/16 BLUE bluebird bio, Inc. coverage initiated by Cantor Fitzgerald 06/03/16 OMER Omeros Corporation coverage initiated by Cantor Fitzgerald 06/03/16 ONCE Spark Therapeutics, Inc. coverage initiated by Cantor Fitzgerald More Recent Events... Locate Industry by Company Enter Symbol: AdChoices Industry Statistics Market Capitalization: 9,619B Price / Earnings: 165.8 Price / Book: 23.4 Net Profit Margin (mrq): 19.7% Price To Free Cash Flow (mrq): -290.2 Return on Equity: 15.4% Total Debt / Equity: 105.0 Dividend Yield: 2.0% View Industry Browser Community Spotlight Most Active Boards Board Popularity CTRX PGLAF NRPH Unusually Active Boards Board Variance CTRX NRPH PDLI RSS Feeds

Add headlines to your personalized My Yahoo Page ( About My Yahoo and RSS )

View post:
Biotechnology Overview: Industry Center - Yahoo Finance